Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 3350 electrolyte oral solution / powder is an osmotic laxative combination developed by Shenyang Dashan Pharmaceutical Technology for the treatment of constipation and for bowel preparation prior to gastrointestinal procedures such as colonoscopy. The formulation contains polyethylene glycol 3350 (PEG 3350) as the primary osmotic agent, supplemented with a balanced mixture of electrolytes including sodium sulfate, sodium bicarbonate, sodium chloride, and potassium chloride. PEG 3350 is a large, non-absorbable polymer that creates an osmotic gradient within the intestinal lumen, drawing water into the bowel to increase stool volume and stimulate peristalsis. The inclusion of electrolytes is designed to maintain an isosmotic balance, preventing the net loss or gain of fluids and ions across the intestinal mucosa, which is critical during the high-volume administration required for effective bowel cleansing. This product is part of the developer's pipeline targeting the Chinese market as a generic alternative to established brands like GoLYTELY.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 3350 + sodium sulfate + sodium bicarbonate + sodium chloride + potassium chloride.